NIKKEI 225
39,596.01 +422.86 (+1.08%) HANG SENG
18,030.84 -42.06 (-0.23%) CRUDE OIL
80.92 +0.09 (+0.11%) GOLD FUTURES
2,326.00 -4.80 (-0.21%) DOW
39,112.16 -299.05 (-0.76%) Bitcoin GBP
48,897.00 +1,337.11 (+2.81%)
CELU Jun 2024 5.000 put
| Previous close | 1.8000 |
| Open | 1.8000 |
| Bid | 1.5000 |
| Ask | 4.4000 |
| Strike | 5.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.8000 - 1.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 25 |
- GlobeNewswire
Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
Company presents results from in vivo studies of PT-CD16VS, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells, in combination with various monoclonal antibodiesFLORHAM PARK, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it presented in vivo data from
- GlobeNewswire
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on May 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Form 10-Q for the quarter ended March 31, 2024 (“Q1 2024 Form 10-
- GlobeNewswire
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
Placental T Cells Demonstrated Greater Persistence, Resistance to Exhaustion and Efficacy Compared To Peripheral Blood Mononuclear CellsFLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that the Journal for ImmunoTherapy of Cancer, a peer-reviewed online journal of the Society for Immunotherapy of
